Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Joshua C. Laperche, Alka Apudhyay, Michelle Eakin, Alexander A Boucher, Laura M. DeCastro, Stephanie H. Guarino, Robert Kribs, Wally R Smith, Vannesia Morgan-Smith, Andrew RW O'Brien, Ashley Lauriello, Jane A. Little, Charlene Sylvestre, Sophie Lanzkron

Blood (2024) 144 (Supplement 1): 5062.

https://doi.org/10.1182/blood-2024-208270

Published: 2024

Journal Articles

Dissecting Mechanistic Differences between EZH2 Gain-of-Function Events in Non-Hodgkin B Cell Lymphomas

Sofia R Smith, George P Souroullas

Blood (2024) 144 (Supplement 1): 4124.

https://doi.org/10.1182/blood-2024-208004

Published: 2024

Journal Articles

“It Was Bootstrap All the Way”: Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States

Francis W Coyne, Deirdra R Terrell, Valerie Lang, Ashley M Jenkins, Allison A. King, Wally R Smith

Blood (2024) 144 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2024-203728

Published: 2024

Journal Articles

Enhanced Pain Sensitivity in Adult Sickle Cell Disease Patients: Potential Mediating Factors

Daniel M Sop, Yue May Zhang, Wally R Smith

Blood (2024) 144 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2024-199317

Published: 2024

Journal Articles

Case Management Time in SCD Adults Is Correlated with ED and Ambulatory Utilization and with Behavioral Health Diagnoses, but Not with Hospitalization and Costs

Wally R Smith, Yue May Zhang, Andrea Burton, Shirley Johnson, Daniel M Sop

Blood (2024) 144 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2024-200970

Published: 2024

Journal Articles

Rethinking Caseloads in Sickle Cell Disease Social Work

Spencer Moorman, Shirley Johnson, Wally R Smith

Blood (2024) 144 (Supplement 1): 7963.

https://doi.org/10.1182/blood-2024-212283

Published: 2024

Journal Articles

Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease

Ashna Jagtiani, Cynthia Sinha, Ashleigh Hawk, Scott Gillespie, Mona Mirbeyk, Fuad El Rassi, Wally R Smith, Lakshmanan Krishnamurti, Soumitri Sil, Nitya Bakshi

Blood (2024) 144 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2024-210575

Published: 2024

Journal Articles

Comparative Analysis of Whole-Brain and Regional Cerebral Blood Flow, Pain Expression, Pain Sensitivity, and Cognitive Function in Adults with Sickle Cell Disease Versus Healthy Controls

Daniel M Sop, Yue May Zhang, Wally R Smith

Blood (2024) 144 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2024-199327

Published: 2024

Journal Articles

Planning Mental Health and Social Support Prescreening Assessments for Adult Sickle Cell Disease Patients: Evaluating Readiness for Curative Therapy

Shirley Johnson, Haylee Hartzog, Cecelia R. Valrie, Yue May Zhang, Andrea Burton, Katrina Dalton, Wally R Smith

Blood (2024) 144 (Supplement 1): 7654.

https://doi.org/10.1182/blood-2024-200954

Published: 2024

Journal Articles

Cerebral Blood Flow and Pain Perception in Sickle Cell Disease: A Mediation Analysis

Daniel M Sop, Yue May Zhang, Wally R Smith

Blood (2024) 144 (Supplement 1): 5339.

https://doi.org/10.1182/blood-2024-199307

Published: 2024

Journal Articles

Effect of Whole-Brain and Regional Silent Cerebral Ischemia on Pain and Cognition Among Adults with Sickle Cell Disease

Daniel M Sop, Yue May Zhang, Wally R Smith

Blood (2024) 144 (Supplement 1): 5305.

https://doi.org/10.1182/blood-2024-199323

Published: 2024

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

Wally R Smith, Donna McClish

Blood (2023) 142 (Supplement 1): 252.

https://doi.org/10.1182/blood-2023-178065

Published: 2023

Journal Articles

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Charles R. Jonassaint, Blaze Armon Eppinger, Dominique Friend, Golie Lorenzo Green, Mia Robinson, Teonna Woolford, DeMitrious Wyant, Janie Davis, Abdulafeez Oluyadi, Ahmar U Zaidi, Holly John, Wally R Smith

Blood (2023) 142 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2023-186710

Published: 2023

Journal Articles

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Mica Ferlis, Daniel Sop, Yue May Zhang, Wally R Smith

Blood (2023) 142 (Supplement 1): 3680.

https://doi.org/10.1182/blood-2023-187483

Published: 2023

Journal Articles

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Guvenc, Deborah Keefe, Kai Grosch, Michele L Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Dei Adomakoh

Blood (2023) 142 (Supplement 1): 272.

https://doi.org/10.1182/blood-2023-185429

Published: 2023

Journal Articles

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Blood (2023) 142 (Supplement 1): 271.

https://doi.org/10.1182/blood-2023-187033

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Dissecting Mechanistic Differences between EZH2 Gain-of-Function Events in Non-Hodgkin B Cell Lymphomas

“It Was Bootstrap All the Way”: Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States

Enhanced Pain Sensitivity in Adult Sickle Cell Disease Patients: Potential Mediating Factors

Case Management Time in SCD Adults Is Correlated with ED and Ambulatory Utilization and with Behavioral Health Diagnoses, but Not with Hospitalization and Costs

Rethinking Caseloads in Sickle Cell Disease Social Work

Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease

Comparative Analysis of Whole-Brain and Regional Cerebral Blood Flow, Pain Expression, Pain Sensitivity, and Cognitive Function in Adults with Sickle Cell Disease Versus Healthy Controls

Planning Mental Health and Social Support Prescreening Assessments for Adult Sickle Cell Disease Patients: Evaluating Readiness for Curative Therapy

Cerebral Blood Flow and Pain Perception in Sickle Cell Disease: A Mediation Analysis

Effect of Whole-Brain and Regional Silent Cerebral Ischemia on Pain and Cognition Among Adults with Sickle Cell Disease

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only